Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
DAPTOMYCIN
CUBIST PHARMACEUTICALS LLC
J01XX09
DAPTOMYCIN
500MG
POWDER FOR SOLUTION
DAPTOMYCIN 500MG
INTRAVENOUS
10ML
Prescription
CYCLIC LIPOPEPTIDES
Active ingredient group (AIG) number: 0152298001; AHFS:
APPROVED
2017-06-30
_ _ _ _ _Page 1 of 72_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR CUBICIN ® _/_CUBICIN ® RF (Daptomycin for Injection) Lyophilized Powder for Solution, For Intravenous Use Only 10 mL vial, 500 mg/vial Antibacterial Agent Cubist Pharmaceuticals LLC Weystrasse 20 6000 Lucerne 6 Lucerne, Switzerland IMPORTED AND DISTRIBUTED BY: Sunovion Pharmaceuticals Canada Inc. 7025 Langer Drive Mississauga ON L5N 0E8 Date of Revision: May 15, 2020 Submission Control Number: 235553 _ _ _ _ _Page 2 of 72_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................5 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................12 DRUG INTERACTIONS ..................................................................................................24 DOSAGE AND ADMINISTRATION ..............................................................................27 ACTION AND CLINICAL PHARMACOLOGY ............................................................36 STORAGE AND STABILITY ..........................................................................................42 SPECIAL HANDLING INSTRUCTIONS .......................................................................43 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................43 PART II: SCIENTIFIC INFORMATION ...............................................................................44 PHARMACEUTICAL INFORMATION ..........................................................................44 CLINICAL TRI Prečítajte si celý dokument